Soo-Jin Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soo-Jin Oh has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Changjoon Justin Lee
Center for Memory and Glioscience, Institute for Basic Science, Daejeon, Republic of Korea
11 shared publications - Min-Ho Nam
Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea
4 shared publications - Chun Whan Choi
Natural Product Research Team, Biocenter, Gyeonggido Business and Science Accelerator, Gyeonggi-Do, Republic of Korea
3 shared publications - Junsung Woo
Center for Glia-Neuron Interaction, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea
3 shared publications - Ki Duk Park
Korea Institute of Science and Technology
3 shared publications - Min Soo Kim
Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea; Division of Bio-Medical Science & Technology, KIST School, Korea National University of Science and Technology (UST), Seoul, 02792, Republic of Korea; KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul, 02447, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in Advanced Science
- p. e78007
Developmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models
Parkinson's disease (PD) involves progressive degeneration of nigrostriatal ventral midbrain dopaminergic (vmDA) neurons and Lewy body proteopathy, necessitating scalable, lineage‐faithful donor cells. However, variability in human pluripotent stem cell (hPSC) differentiation and incomplete ventral midbrain identity limit translational use. Here, we establish a developmentally guided differentiation protocol that reproducibly specifies EN1‐positive vmDA progenitors through temporally optimized SHH, WNT/β‐catenin, and FGF8 signaling. The resulting progenitors mature into vmDA neurons exhibiting stimulus‐dependent dopamine release and maturation‐associated pacemaking activity. Progenitors can be cryopreserved at a defined stage while retaining viability and neurogenic capacity. Functional validation was performed using complementary proteopathy‐based PD models. In vitro, optogenetic induction of α‐synuclein aggregation ( OASIS ) triggered robust aggregate formation and selective degeneration of TH‐positive vmDA neurons in both two‐dimensional cultures and three‐dimensional neurospheroids. In vivo, we established a conditional β23 proteopathy‐based PD mouse model exhibiting progressive nigrostriatal degeneration and motor impairment. Transplantation of hESC‐derived vmDA progenitors into advanced‐stage PD mice led to graft survival, differentiation into vmDA neurons, and significant motor improvement. Together, these findings define a robust vmDA differentiation framework validated across proteopathy‐based disease modeling and transplantation contexts, supporting its application in PD modeling and cell therapy.
- 29 September 2026
- Published by Wiley in Advanced Science
- p. e78007
Open AccessDevelopmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models
Parkinson's disease (PD) involves progressive degeneration of nigrostriatal ventral midbrain dopaminergic (vmDA) neurons and Lewy body proteopathy, necessitating scalable, lineage‐faithful donor cells. However, variability in human pluripotent stem cell (hPSC) differentiation and incomplete ventral midbrain identity limit translational use. Here, we establish a developmentally guided differentiation protocol that reproducibly specifies EN1‐positive vmDA progenitors through temporally optimized SHH, WNT/β‐catenin, and FGF8 signaling. The resulting progenitors mature into vmDA neurons exhibiting stimulus‐dependent dopamine release and maturation‐associated pacemaking activity. Progenitors can be cryopreserved at a defined stage while retaining viability and neurogenic capacity. Functional validation was performed using complementary proteopathy‐based PD models. In vitro, optogenetic induction of α‐synuclein aggregation ( OASIS ) triggered robust aggregate formation and selective degeneration of TH‐positive vmDA neurons in both two‐dimensional cultures and three‐dimensional neurospheroids. In vivo, we established a conditional β23 proteopathy‐based PD mouse model exhibiting progressive nigrostriatal degeneration and motor impairment. Transplantation of hESC‐derived vmDA progenitors into advanced‐stage PD mice led to graft survival, differentiation into vmDA neurons, and significant motor improvement. Together, these findings define a robust vmDA differentiation framework validated across proteopathy‐based disease modeling and transplantation contexts, supporting its application in PD modeling and cell therapy.
- Open Access
- 4 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119019
Vitisin B, extracted from Vitis vinifera, enhances memory function and neuroprotective effects in scopolamine-induced memory-impaired mice
- 4 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119019
Open AccessVitisin B, extracted from Vitis vinifera, enhances memory function and neuroprotective effects in scopolamine-induced memory-impaired mice
- 17 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178363
Neuroprotective effects of Gnetin H from Paeonia lactiflora via CREB-BDNF pathway restoration in a scopolamine-induced memory deficit model
- 17 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178363
Neuroprotective effects of Gnetin H from Paeonia lactiflora via CREB-BDNF pathway restoration in a scopolamine-induced memory deficit model
- Open Access
- 22 August 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-21
Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases
Hemoglobin (Hb) is well known for transporting oxygen in the blood, but its role in the brain remains poorly understood. Here, we identified Hb in the cytosol, mitochondria, and nuclei of hippocampal and substantia nigra astrocytes and dopaminergic neurons. As a pseudoperoxidase, Hb decomposes hydrogen peroxide (H2O2) and mitigates H2O2-induced oxidative damage. However, in Alzheimer’s disease, Parkinson’s disease, and aging, excessive H2O2 diminishes astrocytic Hb, perpetuating a vicious cycle of oxidative stress and neurodegeneration. To counter the harmful effects of aberrant H2O2 production in diseases, we developed KDS12025, a BBB-permeable small molecule that enhances Hb pseudoperoxidase activity 100-fold, even at a low level of Hb. KDS12025 and its analogs achieve this enhancement through its electron-donating amine group, possibly stabilizing the complex between Hb, H2O2, and KDS12025. KDS12025 reduces astrocytic H2O2, alleviates astrogliosis, normalizes Hb, and reverts to a virtuous cycle of redox balance, preventing neurodegeneration without altering the oxygen-transport function of Hb. Gene silencing of Hb abrogates the impact of KDS12025 in both culture and animal models, confirming the necessity of Hb for the effects of KDS12025. KDS12025 extends survival and improves motor function even in severe amyotrophic lateral sclerosis and aging. Furthermore, the enrichment of astrocytic Hb in the nucleolus highlights a novel antioxidative mechanism potentially protecting against nuclear oxidative damage. Our findings suggest that Hb is a new therapeutic target for neurodegenerative diseases, with KDS12025 emerging as a first-in-class approach that enhances Hb pseudoperoxidase activity to reduce H2O2. Increasing Hb pseudoperoxidase activity with KDS12025 mitigates oxidative stress and alleviates neurodegeneration in AD, PD, and ALS patients and increases the degree of aging, with broad applicability for numerous oxidative-stress-driven diseases.
- 22 August 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-21
Open AccessHemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases
Hemoglobin (Hb) is well known for transporting oxygen in the blood, but its role in the brain remains poorly understood. Here, we identified Hb in the cytosol, mitochondria, and nuclei of hippocampal and substantia nigra astrocytes and dopaminergic neurons. As a pseudoperoxidase, Hb decomposes hydrogen peroxide (H2O2) and mitigates H2O2-induced oxidative damage. However, in Alzheimer’s disease, Parkinson’s disease, and aging, excessive H2O2 diminishes astrocytic Hb, perpetuating a vicious cycle of oxidative stress and neurodegeneration. To counter the harmful effects of aberrant H2O2 production in diseases, we developed KDS12025, a BBB-permeable small molecule that enhances Hb pseudoperoxidase activity 100-fold, even at a low level of Hb. KDS12025 and its analogs achieve this enhancement through its electron-donating amine group, possibly stabilizing the complex between Hb, H2O2, and KDS12025. KDS12025 reduces astrocytic H2O2, alleviates astrogliosis, normalizes Hb, and reverts to a virtuous cycle of redox balance, preventing neurodegeneration without altering the oxygen-transport function of Hb. Gene silencing of Hb abrogates the impact of KDS12025 in both culture and animal models, confirming the necessity of Hb for the effects of KDS12025. KDS12025 extends survival and improves motor function even in severe amyotrophic lateral sclerosis and aging. Furthermore, the enrichment of astrocytic Hb in the nucleolus highlights a novel antioxidative mechanism potentially protecting against nuclear oxidative damage. Our findings suggest that Hb is a new therapeutic target for neurodegenerative diseases, with KDS12025 emerging as a first-in-class approach that enhances Hb pseudoperoxidase activity to reduce H2O2. Increasing Hb pseudoperoxidase activity with KDS12025 mitigates oxidative stress and alleviates neurodegeneration in AD, PD, and ALS patients and increases the degree of aging, with broad applicability for numerous oxidative-stress-driven diseases.
- Open Access
- 1 January 2025
- Published by Zoological Research in Zoological Research
- Vol. 46 (1) , 41-53
Novel mouse model of Alzheimer’s disease exhibits pathology through synergistic interactions among amyloid-β, tau, and reactive astrogliosis
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and distinct neuropathological features, including amyloid-β plaques, neurofibrillary tangles, and reactive astrogliosis. Developing effective diagnostic, preventative, and therapeutic strategies for AD necessitates the establishment of animal models that accurately recapitulate the pathophysiological processes of the disease. Existing transgenic mouse models have significantly contributed to understanding AD pathology but often fail to replicate the complexity of human AD. Additionally, these models are limited in their ability to elucidate the interplay among amyloid-β plaques, neurofibrillary tangles, and reactive astrogliosis due to the absence of spatially and temporally specific genetic manipulation. In this study, we introduce a novel AD mouse model (APP/PS1-TauP301L-Adeno mice) designed to rapidly induce pathological symptoms and enhance understanding of AD mechanisms. Neurofibrillary tangles and severe reactive astrogliosis were induced by injecting AAV DJ-EF1a-hTauP301L-EGFP and Adeno-GFAP-GFP viruses into the hippocampi of 5-month-old APP/PS1 mice. Three months post-injection, these mice exhibited pronounced astrogliosis, substantial amyloid-β plaque accumulation, extensive neurofibrillary tangles, accelerated neuronal loss, elevated astrocytic GABA levels, and significant spatial memory deficits. Notably, these pathological features were less severe in AAV-TauP301L-expressing APP/PS1 mice without augmented reactive astrogliosis. These findings indicate an exacerbating role of severe reactive astrogliosis in amyloid-β plaque and neurofibrillary tangle-associated pathology. The APP/PS1-TauP301L-Adeno mouse model provides a valuable tool for advancing therapeutic research aimed at mitigating the progression of AD.
- 1 January 2025
- Published by Zoological Research in Zoological Research
- Vol. 46 (1) , 41-53
Open AccessNovel mouse model of Alzheimer’s disease exhibits pathology through synergistic interactions among amyloid-β, tau, and reactive astrogliosis
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and distinct neuropathological features, including amyloid-β plaques, neurofibrillary tangles, and reactive astrogliosis. Developing effective diagnostic, preventative, and therapeutic strategies for AD necessitates the establishment of animal models that accurately recapitulate the pathophysiological processes of the disease. Existing transgenic mouse models have significantly contributed to understanding AD pathology but often fail to replicate the complexity of human AD. Additionally, these models are limited in their ability to elucidate the interplay among amyloid-β plaques, neurofibrillary tangles, and reactive astrogliosis due to the absence of spatially and temporally specific genetic manipulation. In this study, we introduce a novel AD mouse model (APP/PS1-TauP301L-Adeno mice) designed to rapidly induce pathological symptoms and enhance understanding of AD mechanisms. Neurofibrillary tangles and severe reactive astrogliosis were induced by injecting AAV DJ-EF1a-hTauP301L-EGFP and Adeno-GFAP-GFP viruses into the hippocampi of 5-month-old APP/PS1 mice. Three months post-injection, these mice exhibited pronounced astrogliosis, substantial amyloid-β plaque accumulation, extensive neurofibrillary tangles, accelerated neuronal loss, elevated astrocytic GABA levels, and significant spatial memory deficits. Notably, these pathological features were less severe in AAV-TauP301L-expressing APP/PS1 mice without augmented reactive astrogliosis. These findings indicate an exacerbating role of severe reactive astrogliosis in amyloid-β plaque and neurofibrillary tangle-associated pathology. The APP/PS1-TauP301L-Adeno mouse model provides a valuable tool for advancing therapeutic research aimed at mitigating the progression of AD.
- Open Access
- 25 November 2024
- Published by Wiley in Phytotherapy Research
- Vol. 39 (2) , 593-603
Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity
Monoamine oxidase B (MAO‐B) has emerged as a therapeutic target for Alzheimer's disease (AD) due to its involvement in the synthesis of γ‐aminobutyric acid (GABA) in reactive astrocytes, which inhibits neuronal activity. Suffruticosol B (Suf‐B), isolated from Paeonia lactiflora , is one of the resveratrol oligomers. Although resveratrol oligomers have demonstrated neuroprotective effects, it remains unexplored whether Suf‐B exerts therapeutic effects on AD by targeting MAO‐B. In this study, we investigated whether Suf‐B alleviates AD pathology by mitigating reactive astrogliosis and inhibiting the overproduction of astrocytic GABA. After confirming the MAO‐B inhibitory effect of Suf‐B through MAO‐B enzyme assay, we administered Suf‐B to APP/PS1 AD model mice. To test the potential therapeutic action of Suf‐B in AD, a series of experiments were conducted, including behavioral tests such as the open field test, novel object recognition test, Barnes maze test, passive avoidance test, as well as immunohistochemistry and whole‐cell patch‐clamp recordings. We found that Suf‐B markedly inhibited MAO‐B activity without causing cytotoxicity. Immunohistochemistry and electrophysiology experiments demonstrated that Suf‐B significantly reduced astrocyte reactivity, as well as an aberrant increase in GABA production and tonic GABA release from astrocytes in AD. Behavior test results indicated that Suf‐B treatment restored cognitive function in APP/PS1 mice. In conclusion, Suf‐B effectively reduces excessive GABA production in reactive astrocytes by inhibiting MAO‐B, normalizing aberrant inhibition in hippocampal neurons in an AD mouse model. These results suggest that Suf‐B has potential as a treatment for AD and may be applicable to other brain diseases associated with reactive astrogliosis.
- 25 November 2024
- Published by Wiley in Phytotherapy Research
- Vol. 39 (2) , 593-603
Open AccessSuffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity
Monoamine oxidase B (MAO‐B) has emerged as a therapeutic target for Alzheimer's disease (AD) due to its involvement in the synthesis of γ‐aminobutyric acid (GABA) in reactive astrocytes, which inhibits neuronal activity. Suffruticosol B (Suf‐B), isolated from Paeonia lactiflora , is one of the resveratrol oligomers. Although resveratrol oligomers have demonstrated neuroprotective effects, it remains unexplored whether Suf‐B exerts therapeutic effects on AD by targeting MAO‐B. In this study, we investigated whether Suf‐B alleviates AD pathology by mitigating reactive astrogliosis and inhibiting the overproduction of astrocytic GABA. After confirming the MAO‐B inhibitory effect of Suf‐B through MAO‐B enzyme assay, we administered Suf‐B to APP/PS1 AD model mice. To test the potential therapeutic action of Suf‐B in AD, a series of experiments were conducted, including behavioral tests such as the open field test, novel object recognition test, Barnes maze test, passive avoidance test, as well as immunohistochemistry and whole‐cell patch‐clamp recordings. We found that Suf‐B markedly inhibited MAO‐B activity without causing cytotoxicity. Immunohistochemistry and electrophysiology experiments demonstrated that Suf‐B significantly reduced astrocyte reactivity, as well as an aberrant increase in GABA production and tonic GABA release from astrocytes in AD. Behavior test results indicated that Suf‐B treatment restored cognitive function in APP/PS1 mice. In conclusion, Suf‐B effectively reduces excessive GABA production in reactive astrocytes by inhibiting MAO‐B, normalizing aberrant inhibition in hippocampal neurons in an AD mouse model. These results suggest that Suf‐B has potential as a treatment for AD and may be applicable to other brain diseases associated with reactive astrogliosis.
- 12 March 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 970, 176494
The role of astrocytic γ-aminobutyric acid in the action of inhalational anesthetics
- 12 March 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 970, 176494
The role of astrocytic γ-aminobutyric acid in the action of inhalational anesthetics
- Open Access
- 14 July 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 165, 115139
Novel potent blockers for TWIK-1/TREK-1 heterodimers as potential antidepressants
- 14 July 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 165, 115139
Open AccessNovel potent blockers for TWIK-1/TREK-1 heterodimers as potential antidepressants
- Open Access
- 27 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (3) , 2491
DDC-Promoter-Driven Chemogenetic Activation of SNpc Dopaminergic Neurons Alleviates Parkinsonian Motor Symptoms
Parkinson’s disease (PD) is a neurodegenerative disorder with typical motor symptoms. Recent studies have suggested that excessive GABA from reactive astrocytes tonically inhibits dopaminergic neurons and reduces the expression of tyrosine hydroxylase (TH), the key dopamine-synthesizing enzyme, in the substantia nigra pars compacta (SNpc). However, the expression of DOPA decarboxylase (DDC), another dopamine-synthesizing enzyme, is relatively spared, raising a possibility that the live but non-functional TH-negative/DDC-positive neurons could be the therapeutic target for rescuing PD motor symptoms. However, due to the absence of a validated DDC-specific promoter, manipulating DDC-positive neuronal activity has not been tested as a therapeutic strategy for PD. Here, we developed an AAV vector expressing mCherry under rat DDC promoter (AAV-rDDC-mCherry) and validated the specificity in the rat SNpc. Modifying this vector, we expressed hM3Dq (Gq-DREADD) under DDC promoter in the SNpc and ex vivo electrophysiologically validated the functionality. In the A53T-mutated alpha-synuclein overexpression model of PD, the chemogenetic activation of DDC-positive neurons in the SNpc significantly alleviated the parkinsonian motor symptoms and rescued the nigrostriatal TH expression. Altogether, our DDC-promoter will allow dopaminergic neuron-specific gene delivery in rodents. Furthermore, we propose that the activation of dormant dopaminergic neurons could be a potential therapeutic strategy for PD.
- 27 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (3) , 2491
Open AccessDDC-Promoter-Driven Chemogenetic Activation of SNpc Dopaminergic Neurons Alleviates Parkinsonian Motor Symptoms
Parkinson’s disease (PD) is a neurodegenerative disorder with typical motor symptoms. Recent studies have suggested that excessive GABA from reactive astrocytes tonically inhibits dopaminergic neurons and reduces the expression of tyrosine hydroxylase (TH), the key dopamine-synthesizing enzyme, in the substantia nigra pars compacta (SNpc). However, the expression of DOPA decarboxylase (DDC), another dopamine-synthesizing enzyme, is relatively spared, raising a possibility that the live but non-functional TH-negative/DDC-positive neurons could be the therapeutic target for rescuing PD motor symptoms. However, due to the absence of a validated DDC-specific promoter, manipulating DDC-positive neuronal activity has not been tested as a therapeutic strategy for PD. Here, we developed an AAV vector expressing mCherry under rat DDC promoter (AAV-rDDC-mCherry) and validated the specificity in the rat SNpc. Modifying this vector, we expressed hM3Dq (Gq-DREADD) under DDC promoter in the SNpc and ex vivo electrophysiologically validated the functionality. In the A53T-mutated alpha-synuclein overexpression model of PD, the chemogenetic activation of DDC-positive neurons in the SNpc significantly alleviated the parkinsonian motor symptoms and rescued the nigrostriatal TH expression. Altogether, our DDC-promoter will allow dopaminergic neuron-specific gene delivery in rodents. Furthermore, we propose that the activation of dormant dopaminergic neurons could be a potential therapeutic strategy for PD.
- 1 April 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 91 (8) , 740-752
Astrocytes Render Memory Flexible by Releasing D-Serine and Regulating NMDA Receptor Tone in the Hippocampus
- 1 April 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 91 (8) , 740-752
Astrocytes Render Memory Flexible by Releasing D-Serine and Regulating NMDA Receptor Tone in the Hippocampus